ERBB2 and cancer: To improve selective and immune-mediated eradication of cancer cells, Yuan et al. constructed a multivalent bi-specific nanobioconjugate engager (mBiNE), which could target HER2 expressed by cancer cells and pro-phagocytosis signals at the same time.